Trial Profile
The evaluation of intestinal permeability for damage of mucosal injury from NSAIDS.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary) ; Diclofenac; Omeprazole
- Indications NSAID-induced gastric damage; Rheumatic disorders
- Focus Pharmacodynamics
- 28 Mar 2012 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 28 Mar 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 27 Sep 2011 New trial record